Marian Sobhy Waheeb Azer | Pharmaceutical Sciences | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Marian Sobhy Waheeb Azer — Misr University for Science & Technology, Egypt

Marian Sobhy Waheeb Azer
Affiliation Misr University for Science & Technology
Country Egypt
Subject Area Pharmaceutical Sciences
Event International Top Pharmaceutical Awards
ORCID 0000-0003-1072-9893

Marian Sobhy Waheeb Azer is a researcher associated with pharmaceutical sciences whose ORCID record lists work on drug delivery, formulation development, and pharmacokinetic evaluation. The documented topics include a lamotrigine self-nanoemulsifying delivery system and a ciclopirox olamine emulgel formulation. These subjects reflect practical research interests in dosage-form design, pharmaceutical characterization, and the investigation of drug delivery performance. This article summarizes the available profile information and its relevance to the Innovative Research Award without assuming unverified bibliometric indicators or award outcomes.[1][2]

Abstract

This profile reviews the pharmaceutical research themes documented in Marian Sobhy Waheeb Azer’s ORCID record. The listed publications concern formulation development and drug delivery, including a solid self-nanoemulsifying system for lamotrigine and a topical emulgel containing ciclopirox olamine. These topics are relevant to pharmaceutical formulation, characterization, and evaluation of drug delivery systems. The available record supports a focused account of these research activities, but does not independently establish citation totals, an h-index, or an official award decision.[1][2]

Keywords

Pharmaceutical sciences; drug delivery systems; lamotrigine; self-nanoemulsifying drug delivery; pharmacokinetics; ciclopirox olamine; emulgel formulation; pharmaceutical characterization; formulation research; innovative research.

Introduction

Pharmaceutical research connects the design of dosage forms with the assessment of their properties and potential performance. Delivery-system development can investigate how formulation components influence drug solubilization, release, and absorption, while topical formulations address the requirements of local administration. Azer’s documented work sits within these broad areas. The available publication metadata provides a basis for describing the research topics, although detailed experimental results should be taken from the original articles rather than inferred from titles alone.[1][2]

Research Profile

The supplied ORCID profile identifies Marian Sobhy Azer and lists two research works. One is a 2020 journal article in Drug Design, Development and Therapy on the development, characterization, and in-vivo pharmacokinetic study of a lamotrigine solid self-nanoemulsifying drug delivery system. The other concerns the development and characterization of ciclopirox olamine emulgel for topical drug delivery, listed as published in 2014. The profile does not provide verified Scopus author metrics in the supplied document.[1][2]

Research Contributions

The lamotrigine study addresses a formulation approach designed to support drug delivery and includes characterization and in-vivo pharmacokinetic evaluation in its stated scope. Such work connects pharmaceutical development with the measurement of drug disposition, although specific outcomes require consultation of the full publication. The topical emulgel work focuses on a formulation containing ciclopirox olamine, illustrating a separate dosage-form application. Together, the listed topics show engagement with both systemic delivery research and topical formulation development.[1][2]

Publications

The ORCID profile lists two publications related to pharmaceutical sciences. One focuses on the development and evaluation of a lamotrigine drug delivery system, while the other examines the formulation and characterization of ciclopirox olamine emulgel for topical drug delivery.[1][2]

Research Impact

The documented subjects are relevant to formulation scientists and pharmaceutical researchers investigating delivery strategies and dosage-form characteristics. However, research impact should be assessed using verified evidence such as citation records, independent adoption, reproducibility, and influence on subsequent work. Citation counts and h-index values are not present in the supplied ORCID document, so no numerical impact claim is made here. Further evaluation can use indexed publication records and the full-text articles.[1][3]

Award Suitability

The listed work provides subject-matter relevance to an Innovative Research Award in pharmaceutical sciences, particularly through formulation development and drug delivery investigations. A fair assessment would examine originality, methodological quality, reproducibility, publication integrity, practical significance, and the candidate’s specific contribution to each study. The information presented here is a profile summary, not confirmation of nomination, selection, or receipt of an award. Final eligibility and recognition must be verified with the award organizer.[4]

Conclusion

Marian Sobhy Waheeb Azer’s supplied ORCID record documents research related to lamotrigine delivery systems and ciclopirox olamine topical formulation. These subjects are pertinent to pharmaceutical formulation and evaluation. The record offers a starting point for academic recognition, while a complete assessment requires the original articles, verified bibliometric data, and evidence of individual research contributions. Readers should consult the linked primary sources for publication details and the official award website for current event information.

References

  1. Azer, M. S. (2020). Development, Characterization, and in-vivo Pharmacokinetic Study of Lamotrigine Solid Self-Nanoemulsifying Drug Delivery System. Drug Design, Development and Therapy. DOI: 10.2147/DDDT.S263898.
  2. Azer, M. S. (2014). Development and Characterization of Ciclopirox Olamine Emulgel for Topical Drug Delivery. Inventi Impact: Pharm Tech. Publication details transcribed from the supplied ORCID profile. https://inventi.in/journal/article/1/7319/Inventi%20Impact:%20Pharm%20Tech/Pharmaceutical
  3. ORCID. (n.d.). Marian Sobhy Azer: Researcher record and works. https://orcid.org/0000-0003-1072-9893.
  4. International Top Pharmaceutical Awards. (n.d.). Official award website. Award eligibility and recognition details should be confirmed with the organizer. https://toppharmaceutical.org/.

Pallab Mandal | Pharmacology | Best Innovation Award

Published on by Top Pharmaceutical

Best Innovation Award

Pallab Mandal – Ami Polymer Pvt Ltd

Pallab Mandal
Affiliation Ami Polymer Pvt Ltd
Country India
Scopus ID 57190006013
Documents 17
Citations 88
h-index 6
Subject Area Pharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0003-3869-7678

Pallab Mandal is a pharmaceutical research scientist associated with bioanalytical research, drug analysis, and pharmacokinetic investigations. This academic recognition profile summarizes his documented research activities and publication record in pharmacology and pharmaceutical analysis. According to his ORCID record, Mandal’s research interests include liquid chromatography tandem mass spectrometry, pharmacokinetics, pharmacodynamics, bioequivalence studies, drug analysis in human plasma, metabolite analysis, and protein analysis. His listed professional activities also include bioanalytical research, university teaching, and pharmaceutical association membership. [1]

Abstract

Pallab Mandal’s documented publications address pharmaceutical analysis, analytical method development, bioanalytical validation, and pharmacokinetic investigations. His work includes the application of liquid chromatography tandem mass spectrometry to pharmaceutical compounds and biological samples. These research themes provide the academic context for considering his profile for the Best Innovation Award. The article summarizes available records without asserting an independently confirmed award decision. [1]

Keywords

Pallab Mandal, Best Innovation Award, pharmacology, bioanalysis, LC-MS/MS, bioequivalence, pharmaceutical analysis, pharmacokinetics, analytical method validation, drug development.

Introduction

Pharmaceutical research depends on reliable analytical procedures to identify and quantify drug compounds. Validated bioanalytical methods support the measurement of substances in biological samples and can contribute to pharmacokinetic and bioequivalence investigations. Mandal’s publication record addresses these areas through analytical methods developed for a range of pharmaceutical compounds. [2]

Research Profile

The supplied ORCID record identifies Mandal as an LC-MS/MS bioanalyst and research scientist involved in bioequivalence studies. It records professional bioanalytical employment beginning in 2015, university-related teaching activity, and postgraduate research affiliation. His professional record also lists membership in the Indian Pharmaceutical Association. [1]

Research Contributions

Mandal’s listed studies investigate analytical approaches for compounds including miltefosine, azelnidipine, vilazodone, diosmetin, hesperetin, metformin, and teneligliptin. Several publications describe LC-MS/MS methods for human plasma analysis and pharmacokinetic applications. His research record also includes work on pharmaceutical packaging and drug-analysis procedures, reflecting interests in analytical reliability and pharmaceutical practice. [2] [3]

Publications

Representative publications listed in his ORCID record include a pharmaceutical packaging audit published in 2022, a miltefosine analytical method study from 2022, an azelnidipine bioanalytical method study from 2022, a vilazodone quantification study from 2021, and a diosmetin and hesperetin analysis from 2019. The DOI links in the references provide direct access to these bibliographic records and their available publication details. [4] [5]

Research Impact

The supplied profile metrics report 17 documents, 88 citations, and an h-index of 6. These figures are provided for this article and have not been independently verified against a live database. Citation counts may change over time or differ between platforms. The publication topics indicate potential practical relevance to pharmaceutical analysis, although individual findings should be assessed through their methods, results, and reproducibility. [1]

Award Suitability

Mandal’s research themes provide a basis for consideration in a pharmaceutical innovation recognition category. A comprehensive assessment should examine methodological originality, reproducibility, practical application, documented individual contributions, and independent peer review. The listed publications establish relevant research activity, but award eligibility and final selection remain matters for the award organizers and their evaluation process.

Conclusion

Pallab Mandal’s research profile focuses on pharmaceutical bioanalysis, LC-MS/MS-based analytical methods, and pharmacokinetic applications. His listed publications cover multiple drug compounds and related pharmaceutical topics. This Best Innovation Award article presents a structured academic overview with linked researcher records and DOI references for readers seeking to examine the available evidence independently.

References

  1. ORCID. (n.d.). Pallab Mandal: Researcher record and works. ORCID. https://orcid.org/0000-0003-3869-7678
  2. Mandal, P., et al. (2022). An audit on design of pharmaceutical packaging. Journal of Packaging Technology and Research. https://doi.org/10.1007/s41783-022-00141-8
  3. Mandal, P., et al. (2022). Analytical method development and validation of miltefosine by liquid chromatography tandem mass spectrometry. Research Journal of Pharmacy and Technology. https://doi.org/10.52711/0974-360x.2022.00693
  4. Mandal, P., et al. (2022). A novel validated bioanalytical method for azelnidipine in Indian human plasma by LC-MS/MS. Indian Drugs. https://doi.org/10.53879/id.59.05.12787
  5. Mandal, P., et al. (2021). Determination and quantitation of vilazodone hydrochloride in human plasma by LC-ESI-MS/MS. Journal of Analytical & Pharmaceutical Research. https://doi.org/10.15406/japlr.2021.10.00361

Sepideh Khorasani | Food Science and Technology | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Sepideh Khorasani
Affiliation Shahid Bahonar University of Kerman
Country Iran
Scopus ID 57194834910
Documents 24
Citations 5,232
h-index 10
Subject Area Food Science and Technology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-5454-5837

Sepideh Khorasani – Shahid Bahonar University of Kerman

Sepideh Khorasani is a researcher in Food Science and Technology affiliated with Shahid Bahonar University of Kerman, Iran. Her documented research includes food nanotechnology, nutraceutical delivery, food preservation, pistachio quality, plant-derived bioactive compounds, and functional food systems. Her publication record demonstrates interdisciplinary connections between food science, nanocarrier technologies, nutrition, and applied agricultural research. [1]

Abstract

Sepideh Khorasani’s research profile reflects sustained activity in Food Science and Technology, with particular attention to food nanotechnology, nutraceutical delivery, food preservation, and plant-derived bioactive compounds. Her published work addresses nanoliposomes, food-grade nanocarriers, pistachio preservation, antimicrobial applications, and functional food development. These studies connect fundamental food science with practical approaches for improving stability, bioavailability, safety, and shelf life. [2]

Keywords

Food Science and Technology; Food Nanotechnology; Nanoliposomes; Nutraceuticals; Food Preservation; Pistachio Research; Functional Foods; Bioactive Compounds; Nanocomposite Packaging; Antimicrobial Applications.

Introduction

Food science increasingly incorporates nanotechnology and advanced delivery systems to address challenges involving ingredient stability, bioavailability, preservation, and controlled functionality. Khorasani’s research contributes to this area through studies involving nanoliposomes, nutraceutical molecules, plant-derived compounds, and food packaging technologies. Her affiliation with Shahid Bahonar University of Kerman places this work within an established academic environment focused on food and agricultural sciences. [3]

Research Profile

The research profile encompasses both food-focused and interdisciplinary investigations. Published studies include nanoliposome technology for food and nutraceutical industries, multifunctional nanocarriers for nutraceutical and dietary molecules, multigrain food formulation, and preservation of fresh pistachios. The portfolio also includes research on essential oils, antimicrobial activity, saffron-derived materials, and foodborne pathogens. [4]

Research Contributions

A notable contribution is the application of nanocarrier concepts to food and nutraceutical systems. Research on nanoliposomes examines their potential for encapsulating dietary and bioactive molecules, while related work considers lipidic nanocarriers from a broader delivery perspective. Other studies apply nanotechnology to food packaging and preservation, including approaches involving zinc nanoparticles and pistachio green hull essential oil. [1]

Publications

Selected publications demonstrate a progression from food nanotechnology and nutraceutical delivery toward applied preservation and bioactive-material research. The studies include peer-reviewed articles in Trends in Food Science & Technology, Molecules, Food Science & Nutrition, Waste and Biomass Valorization, and Scientific Reports. These publications provide a representative view of the research themes associated with Khorasani’s academic profile.[4]

Research Impact

The supplied research metrics list 24 documents, 5,232 citations, and an h-index of 10. Bibliographic sources also identify research contributions involving nanocarriers, food preservation, pistachio quality, and nutraceutical systems. Citation and publication metrics can vary between databases and update dates; therefore, the figures presented here are treated as profile data supplied for this recognition page.[4]

Award Suitability

The documented research themes are relevant to an academic recognition category emphasizing innovative research in food, pharmaceutical, and nutraceutical interfaces. Work involving delivery systems, bioactive compounds, antimicrobial applications, and food preservation illustrates the application of scientific methods to practical problems. The International Top Pharmaceutical Awards provides the event context supplied for this recognition. [5]

Conclusion

Sepideh Khorasani’s research record represents an interdisciplinary body of work connecting Food Science and Technology with nanotechnology, nutraceutical delivery, food preservation, and bioactive materials. Her publications address both methodological and applied questions across food systems. The documented profile, publications, and supplied research metrics provide the academic basis for presenting her work within an Innovative Research Award context.

References

  1. Elsevier. (n.d.). Scopus author details: Sepideh Khorasani, Author ID 57194834910. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57194834910
  2. Khorasani, S., Danaei, M., & Mozafari, M. R. (2018). Nanoliposome technology for the food and nutraceutical industries. Trends in Food Science .
    https://doi.org/10.1016/j.tifs.2018.07.009
  3. Zarrabi, A., Alipoor Amro Abadi, M., Khorasani, S., Mohammadabadi, M. R., Jamshidi, A., Torkaman, S., Taghavi, E., Mozafari, M. R., & Rasti, B. (2020). Nanoliposomes and Tocosomes as Multifunctional Nanocarriers for the Encapsulation of Nutraceutical and Dietary Molecules. Molecules. https://doi.org/10.3390/molecules25030638
  4. Kamali Rousta, L., Ghandehari Yazdi, A. P., Khorasani, S., Tavakoli, M., Ahmadi, Z., & Amini, M. (2021). Optimization of novel multigrain pasta and evaluation of physicochemical properties: using D-optimal mixture design. Food Science & Nutrition,
    https://doi.org/10.1002/fsn3.2514
  5. Khorasani, S., Ghandehari Yazdi, A. P., Saadatfar, A., Kamali Rousta, L., Nejatian, M., Abarian, M., & Jafari, S. M. (2022). Valorization of Saffron Tepals for the Green Synthesis of Silver Nanoparticles and Evaluation of Their Efficiency Against Foodborne Pathogens. Waste and Biomass Valorization.
    https://doi.org/10.1007/s12649-022-01791-0

Shweta Patel | Women Researcher Award | Pharmaceutical

Published on by Top Pharmaceutical

Women Researcher Award

Shweta Patel — Gokul Global University, India

Shweta Patel
Affiliation Gokul Global University
Country India
Scopus ID 59600471600
Documents 17
Citations 25
h-index 3
Subject Area Pharmaceutical
Event International Top Pharmaceutical Awards
ORCID 0000-0002-8893-3248

Shweta Patel is a researcher associated with Gokul Global University, India, whose documented scholarly record includes pharmaceutical and medicinal chemistry research. Her recent work includes heterocyclic compound synthesis, antimicrobial evaluation, antioxidant studies, and ADME-oriented investigations. The available research record also identifies contributions involving green synthesis and computational assessment of chemical compounds.[1] :contentReference[oaicite:0]{index=0}

Abstract

The research profile of Shweta Patel reflects activity across pharmaceutical chemistry, medicinal chemistry, chemical synthesis, antimicrobial research, and computational drug-development approaches. Available records document studies involving pyran, oxadiazole, thiazolidinone, chromene, quinoline, and related heterocyclic frameworks. Several publications combine synthesis and characterization with biological or ADME-oriented evaluation, providing a multidisciplinary basis for pharmaceutical research.[2]

Keywords

Pharmaceutical Chemistry; Medicinal Chemistry; Drug Discovery; Heterocyclic Chemistry; Antimicrobial Research; Antioxidant Activity; ADME Prediction; Green Synthesis; Chemical Synthesis; Pharmaceutical Innovation.

Introduction

Pharmaceutical research increasingly integrates synthetic chemistry with biological screening and computational approaches to identify compounds with potentially useful pharmacological characteristics. Patel’s documented publications reflect this interdisciplinary pattern, particularly through investigations of heterocyclic derivatives and their antimicrobial or antioxidant properties. The research record also includes studies applying ADME prediction and green synthetic methodologies to pharmaceutical chemistry problems.[3]

Research Profile

The available Scopus-linked record identifies Shweta Patel with Scopus Author ID 59600471600, while the supplied ORCID record identifies 33 works across articles, book chapters, and other research outputs. The documented publication history spans at least 2023–2026 and includes journals such as the Journal of Pharmaceutical Innovation, Russian Journal of General Chemistry, Russian Journal of Organic Chemistry, and related scientific publications.[4]

Research Contributions

A recurring research theme is the design and synthesis of heterocyclic compounds followed by structural characterization and biological evaluation. Recent records include pyrazole–oxadiazole–thioacetamide hybrids, 1,8-naphthyridine–thiazolidinone derivatives, chromene–thiazolidinedione hybrids, and oxadiazole thioacetamide derivatives. These studies demonstrate an emphasis on connecting molecular design with antimicrobial activity and ADME-related assessment.[5]

Publications

The publication portfolio includes recent journal articles and earlier studies in synthetic and pharmaceutical chemistry. Documented examples include work on 2H-pyran derivatives, 1,3,4-oxadiazole derivatives, modified 2-oxochromane compounds, 1,4-dihydropyrano[2,3-c]pyrazoles, and 2-amino-4H-pyrans. The record also contains research on environmental applications of functionalized nanoparticles and pharmaceutical sedation comparisons.[4]

Research Impact

The supplied profile records 17 documents, 25 citations, and an h-index of 3 for the award profile. These metrics provide quantitative indicators of scholarly output and citation activity, although bibliometric values can change as databases are updated. The broader ORCID-linked record indicates additional works and research outputs beyond the selected metrics supplied for this recognition page.[4]

Award Suitability

The documented combination of pharmaceutical chemistry publications, heterocyclic synthesis, antimicrobial evaluation, antioxidant investigations, and ADME-focused research provides a clear scholarly basis for consideration within a pharmaceutical research recognition context. The record contains multiple peer-reviewed journal articles with DOI identifiers, allowing individual publications to be independently located and evaluated. Award consideration should be based on the applicable criteria and verified supporting documentation. [4]

Conclusion

Shweta Patel’s documented research activity encompasses several interconnected areas of pharmaceutical and medicinal chemistry, with particular emphasis on synthetic heterocyclic chemistry and biological evaluation. Her publication record includes recent DOI-indexed studies as well as earlier research on green synthesis and antimicrobial compounds. The available identifiers and publication records provide a basis for further scholarly verification and recognition assessment.

References

 

  1. Elsevier. (n.d.). Scopus author details: Shweta Patel, Author ID 59600471600. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59600471600
  2. Patel, S. A. (2026). Development of a Novel 1,8-Naphthyridine–Thiazolidinone Derivative: Synthesis, Spectral Characterization, Antimicrobial Profiling, and ADME Prediction. Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-026-10426-z
  3. Patel, S. (2026). Structure–Activity Relationship and ADME-Guided Optimization of 4H-Chromene-3-Carbonitrile Derivatives as Promising Antimicrobial Agents. Research Square. https://doi.org/10.21203/rs.3.rs-8718836/v1
  4. Patel, S. (2026). Design and Synthesis of Pyrazole–Oxadiazole–Thioacetamide Hybrids with Antimicrobial and Antioxidant Properties. Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-026-10720-w
  5. Patel, S. (2026). Molecular hybridization approach toward quinoline–thiazolidinedione derivatives: synthesis, DPPH radical scavenging activity, and ADME prediction. Journal of the Iranian Chemical Society. https://doi.org/10.1007/s13738-026-03636-2

Jean Noel Nyemb | Natural Products Chemistry | Research Excellence Award

Published on by Top Pharmaceutical

Research Excellence Award

Jean Noel Nyemb
Affiliation The University of Maroua
Country Cameroon
Scopus ID 56136932800
Documents 27
Citations 227
h-index 8
Subject Area Natural Products Chemistry
Event International Top Pharmaceutical Awards
ORCID 0000-0001-5069-6737

Jean Noel Nyemb – The University of Maroua

Jean Noel Nyemb is a researcher associated with The University of Maroua, Cameroon, whose documented scholarly profile is centered on natural products chemistry, compound isolation, organic synthesis and bioactivities. His research record includes studies connecting phytochemical investigation with biological evaluation, molecular docking and related computational approaches. [1]

Abstract

Jean Noel Nyemb’s documented research profile reflects sustained activity in natural products chemistry and related pharmaceutical research. His publications address isolation and characterization of natural compounds, antimicrobial and antioxidant activities, enzyme inhibition, molecular docking and ADMET-oriented investigations. The ORCID record lists 50 of 53 works and records professional and research activities associated with The University of Maroua. [1]

Keywords

Natural Products Chemistry; compound isolation; organic synthesis; bioactivities; phytochemistry; molecular docking; antimicrobial activity; antioxidant activity; pharmacological evaluation; medicinal plants.

Introduction

Natural products research integrates chemistry, biological evaluation and pharmacological investigation to identify compounds of potential scientific and therapeutic interest. Nyemb’s documented works demonstrate this interdisciplinary pattern through investigations of medicinal plants, propolis, isolated metabolites and bioactive constituents. [2] The record also includes computational studies that complement experimental observations through docking and ADMET analysis. [3]

Research Profile

The ORCID record identifies Jean Noël Nyemb with The University of Maroua and lists research keywords including natural products, compound isolation, organic synthesis and bioactivities. His publication portfolio covers phytochemical studies, natural product characterization, enzyme inhibition, antimicrobial research and computational assessment of bioactive compounds. The profile also records peer-review activity across journals in natural products, chemistry, pharmacology and related fields.[4]

Research Contributions

A recurring contribution is the investigation of chemically characterized natural products alongside biological activity measurements. Reported studies include antibacterial, antiradical, antiplasmodial, α-glucosidase, α-amylase and cholinesterase-related investigations. Other publications extend this approach through molecular docking, molecular dynamics and ADMET profiling, providing computational perspectives on compound–target interactions. [5]

Publications

The documented publication record includes articles in Natural Product Research, Journal of Ethnopharmacology, Discover Chemistry, Drug Target Insights, ChemistrySelect and related journals. Recent work includes studies of antiplasmodial compounds, antibacterial constituents, molecular docking and bioactivity evaluation. The bibliography below presents selected publications in APA-style form with DOI links for direct verification.[5]

Research Impact

The supplied research profile reports 27 documents, 227 citations and an h-index of 8. These metrics provide quantitative indicators of indexed scholarly output and citation activity, while the publication record provides additional evidence of recurring research themes. The ORCID record also documents peer-review participation for journals including Natural Product Research and other chemistry, pharmacology and natural-products publications. [1]

Award Suitability

For the Research Excellence Award, the documented profile provides several research-relevant areas for consideration, including natural products chemistry, compound isolation, biological activity evaluation and computational investigation. The publication portfolio demonstrates continuity across these themes and includes peer-reviewed articles with identifiable DOI records. [2] Final recognition should be determined according to the award’s established evaluation criteria and verification procedures.

Conclusion

Jean Noel Nyemb’s documented academic record presents a research profile focused on natural products chemistry and bioactive compound investigation. His works combine phytochemical characterization with biological and computational approaches, while indexed publication and citation information provides measurable evidence of scholarly activity. The record therefore provides a structured basis for academic recognition within a pharmaceutical research awards context.[1]

References

  1. Nyemb, J. N. (n.d.). ORCID record: Jean Noël Nyemb, ORCID 0000-0001-5069-6737. ORCID.
    https://orcid.org/0000-0001-5069-6737
  2. Nyemb, J. N., et al. (2022). Antimicrobial and α-glucosidase inhibitory activities of chemical constituents from Gardenia aqualla (Rubiaceae). Natural Product Research.
    https://doi.org/10.1080/14786419.2022.2031187
  3. Nyemb, J. N., et al. (2026). Molecular docking, dynamics simulations, and ADMET evaluation of some indole alkaloids and phenolic compounds from Campylospermum genus. Discover Chemistry.
    https://doi.org/10.1007/s44371-026-00814-2
  4. Munvera, A. M., Ngenge, T. A., Wache Ouahouo, B. M., Kucukaydin, S., Nyemb, J. N., et al. (2023). Cholinesterase, α-glucosidase, tyrosinase and urease inhibitory activities of compounds from fruits of Rinorea oblongifolia. Natural Product Research.
    https://doi.org/10.1080/14786419.2023.2176491
  5. Djoko, C. T., Nyemb, J. N., Sakava, P., et al. (2024). Molecular docking and in silico ADMET evaluation of compounds from Erythrina senegalensis. Journal of Phytomolecules and Pharmacology.
    https://doi.org/10.56717/jpp.2024.v03i01.026

Samah Algharib | Immunotherapy | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Samah Algharib — Mississippi State University, United States

Samah Algharib
Affiliation Mississippi State University
Country United States
Scopus ID 57211476541
Documents 42
Citations 1,190
h-index 17
Subject Area Immunotherapy
Event International Top Pharmaceutical Awards
ORCID 0000-0002-3336-2855

Samah Algharib is affiliated with Mississippi State University and works within the broad research area of immunotherapy. The documented research record includes studies addressing antibacterial treatment strategies and veterinary infectious disease, including responsive nanogels, controlled-release hydrogels, and diagnostic perspectives related to bovine mastitis. [1] [2] [3]

Abstract

Samah Algharib, affiliated with Mississippi State University, is associated with research spanning immunotherapy, antibacterial treatment strategies, drug delivery, and veterinary infectious disease. The documented publication record includes investigations of pH- and gelatinase-responsive florfenicol nanogels against Staphylococcus aureus, slow-release florfenicol hydrogels for intestinal bacterial infections, and contemporary approaches to bovine mastitis diagnosis. These studies collectively address therapeutic delivery, antimicrobial effectiveness, controlled release, and disease identification. The supplied research profile records 42 documents, 1,190 citations, and an h-index of 17, providing bibliometric context for the recognition of research activity in pharmaceutical and biomedical applications. [1] [2] [3]

Keywords

Immunotherapy; antibacterial therapy; florfenicol; nanogels; hydrogels; controlled drug release; Staphylococcus aureus; bovine mastitis; veterinary medicine; pharmaceutical research.

Introduction

Research associated with Samah Algharib addresses biomedical and pharmaceutical questions involving antimicrobial treatment and disease management. Published work examines responsive florfenicol nanogels and hydrogels designed to improve therapeutic delivery, while related veterinary research considers contemporary diagnostic approaches for bovine mastitis. These topics connect pharmaceutical formulation with infectious-disease applications. [1] [2] [3]

Research Profile

The supplied profile identifies immunotherapy as the principal subject area, alongside research themes involving antimicrobial agents, drug-delivery systems, bacterial infections, and veterinary health. The publications demonstrate attention to formulation characteristics, release behavior, antibacterial activity, and diagnostic considerations, providing a multidisciplinary context for pharmaceutical and biomedical investigation. [1] [2] [3]

Research Contributions

The documented studies contribute to research on responsive and controlled antimicrobial delivery. One study investigates pH- and gelatinase-responsive florfenicol nanogels against Staphylococcus aureus, while another examines slow-release florfenicol hydrogels for intestinal bacterial infections. Related work reviews concepts and advances in bovine mastitis diagnosis, connecting treatment research with disease detection. [1] [2] [3]

Publications

The supplied publication set includes research on enhanced antibacterial effects of pH/gelatinase-responsive florfenicol nanogels, manipulated slow release of florfenicol hydrogels, and basic concepts and recent advances in bovine mastitis diagnosis. These publications collectively reflect research interests spanning pharmaceutical formulation, antimicrobial intervention, controlled release, veterinary disease management, and diagnostic science. [1] [2] [3]

Research Impact

The supplied bibliometric profile records 42 documents, 1,190 citations, and an h-index of 17. These indicators provide quantitative context for the reach of the indexed research record, while the cited publications demonstrate applications in antimicrobial treatment, drug delivery, and veterinary diagnostics. Bibliometric measures should be interpreted alongside publication quality and research context. [1] [2] [3]

Award Suitability

For an Innovative Research Award, the documented work provides evidence of research involving responsive nanogels, controlled-release hydrogels, antibacterial treatment, and veterinary diagnostic perspectives. The combination of formulation-oriented pharmaceutical research and infectious-disease applications demonstrates identifiable innovation themes that can be considered alongside the supplied publication record, citation indicators, affiliation, and the specific criteria established by the awarding organization. [1] [2] [3]

Conclusion

Samah Algharib’s documented research profile encompasses immunotherapy-related interests, antimicrobial delivery, florfenicol formulations, bacterial infection treatment, and bovine mastitis diagnostics. The supplied record combines publication activity with reported citation indicators and research addressing practical biomedical and veterinary challenges. These materials provide a structured basis for academic recognition under the stated Innovative Research Award category. [1] [2] [3]

References

  1. Enhanced antibacterial effect of pH/gelatinase-responsive florfenicol nanogels against Staphylococcus aureus. (2025). PubMed.
    https://pubmed.ncbi.nlm.nih.gov/40292404/
  2. Manipulated slow release of florfenicol hydrogels for effective treatment of anti-intestinal bacterial infections. (n.d.). International Journal of Nanomedicine, Dove Medical Press.
    https://www.dovepress.com/manipulated-slow-release-of-florfenicol-hydrogels-for-effective-treatm-peer-reviewed-fulltext-article-IJN
  3. Basic concepts, recent advances, and future perspectives in the diagnosis of bovine mastitis. (2023). Journal of Veterinary Science. https://doi.org/10.4142/jvs.23147
    https://vetsci.org/DOIx.php?id=10.4142/jvs.23147

Ubaldo Armato | Drug Delivery Systems | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Ubaldo Armato
University of Verona, Italy

Ubaldo Armato
Affiliation University of Verona
Country Italy
Scopus ID 16502026200
Documents 179
Citations 3,838
h-index 34
Subject Area Drug Delivery Systems
Event International Top Pharmaceutical Awards

The Innovative Research Award recognizes scholarly excellence and sustained contributions to pharmaceutical and biomedical sciences. Ubaldo Armato of the University of Verona has established a notable academic profile through multidisciplinary investigations involving cellular biology, pathology, and drug delivery systems. His publication record and citation impact demonstrate consistent engagement with internationally recognized scientific research activities.[1]

Abstract

This article summarizes the academic achievements of Ubaldo Armato in relation to the Innovative Research Award. The assessment considers publication productivity, citation influence, and scientific engagement within pharmaceutical and biomedical research domains. Particular attention is given to contributions associated with drug delivery systems, pathology, and translational biomedical sciences. The review highlights measurable scholarly indicators and research dissemination activities documented through recognized academic databases.[1]

Keywords

Innovative Research Award, Ubaldo Armato, Drug Delivery Systems, Biomedical Sciences, Pharmaceutical Research, Scopus Author Profile, Citation Impact, Research Excellence.

Introduction

Academic awards provide recognition for scientific advancement and sustained scholarly engagement. Researchers working across pharmaceutical and biomedical disciplines contribute significantly to the understanding of disease mechanisms, therapeutic innovation, and translational medicine. Within this context, Ubaldo Armato’s scholarly record reflects an established commitment to research dissemination and interdisciplinary collaboration. His academic profile aligns with the objectives commonly associated with international scientific recognition programs.[2]

Research Profile

Ubaldo Armato is affiliated with the University of Verona and has contributed to numerous peer-reviewed publications indexed within international databases. His scholarly activities encompass cellular pathology, neurobiology, oncology, and pharmaceutical sciences. The documented publication count, citation metrics, and h-index collectively indicate long-term participation in impactful scientific research. These indicators are frequently utilized in evaluating academic productivity and research visibility.[1]

Research Contributions

Research contributions associated with Armato’s work include investigations into cellular responses, disease progression mechanisms, and biomedical applications relevant to therapeutic development. His studies have supported scientific understanding in areas connected to pharmaceutical innovation and biological systems analysis. Collaborative publications have further expanded the reach of these findings within international research communities. Such contributions continue to inform future studies and interdisciplinary inquiry.[3]

Publications

The research portfolio includes journal articles, collaborative studies, reviews, and biomedical investigations published through recognized academic channels. Publications have addressed molecular mechanisms, pathology, therapeutic approaches, and broader pharmaceutical applications. Citation activity associated with these works reflects continuing scholarly engagement and relevance within scientific literature. Multiple outputs have contributed to ongoing discussions in biomedical and pharmaceutical research communities.[1]

Research Impact

Research impact may be evaluated through citation frequency, interdisciplinary influence, and the continued use of published findings by subsequent investigators. With more than three thousand citations and a substantial h-index, Armato’s work demonstrates measurable visibility within academic literature. These metrics indicate that published studies have contributed to ongoing scientific dialogue and knowledge development. Research impact remains an important consideration in international award evaluations.[3]

Award Suitability

The Innovative Research Award emphasizes scholarly excellence, innovation, and meaningful contributions to scientific advancement. Based on publicly available academic indicators, publication records, and citation performance, Ubaldo Armato presents a profile consistent with the objectives of international research recognition initiatives. His multidisciplinary work and documented research productivity support consideration within competitive academic award frameworks. Evaluation remains subject to the criteria established by the awarding organization.[1]

Conclusion

Ubaldo Armato’s academic record reflects sustained participation in biomedical and pharmaceutical research. Publication activity, citation influence, and interdisciplinary engagement demonstrate a measurable contribution to scientific knowledge. These characteristics align with the broader objectives of recognizing impactful scholarship and innovation. The Innovative Research Award provides a framework through which such achievements may be formally acknowledged within the international scientific community.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Ubaldo Armato, Author ID 16502026200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=16502026200
  2. Jiang, L., Yang, S., Zhang, F., … De Santis, D., & Li, H. Cell-Free Adipose Liquid Extract Combined with Vascularized Lymph Node Transfer for Treating Lymphedema: Implications for Human Therapy.
    https://pubmed.ncbi.nlm.nih.gov/42479418/
  3. Chiarini, A.M., Armato, U., Gui, L., … Chang, S., & Dal Prà, I. Early divergent modulation of NLRP2′s and NLRP3′s inflammasome sensors vs. AIM2′s one by signals from Aβ·Calcium-sensing receptor complexes in human astrocytes.
    https://pubmed.ncbi.nlm.nih.gov/39426463/

Mohamed Husseiny Elsayed | Immunotherapy | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Mohamed Husseiny Elsayed
Beckman Research Institute of City of Hope

Mohamed Husseiny Elsayed
Affiliation Beckman Research Institute of City of Hope
Country United States
Scopus ID 8580986700
Documents 65
Citations 6,388
h-index 28
Subject Area Immunotherapy
Event Name International Top Pharmaceutical Awards
ORCID 0000-0002-3470-2858

The Innovative Research Award recognizes distinguished scientific achievements that contribute to the advancement of biomedical and pharmaceutical sciences. Mohamed Husseiny Elsayed has developed a research profile characterized by sustained contributions to immunotherapy, translational oncology, and therapeutic innovation. His scholarly output has supported the understanding of immune-mediated mechanisms and their application in clinical research environments.[1]

Abstract

This article presents an academic overview of Mohamed Husseiny Elsayed and his suitability for recognition through the Innovative Research Award. The assessment is based on publication activity, citation performance, research visibility, and contributions to immunotherapy-related investigations. Available scholarly indicators demonstrate consistent engagement with impactful biomedical research and collaborative scientific advancement.[2]

Keywords

Immunotherapy, translational medicine, oncology research, biomedical innovation, pharmaceutical sciences, clinical investigation, scientific impact, therapeutic development.

Introduction

Modern biomedical research increasingly depends on interdisciplinary approaches that integrate molecular biology, immunology, and clinical sciences. Researchers working in these domains contribute to the development of therapeutic strategies designed to address complex diseases. Mohamed Husseiny Elsayed has participated in this evolving scientific landscape through research efforts focused on immunotherapeutic applications and translational outcomes.[3]

Research Profile

The researcher is affiliated with the Beckman Research Institute of City of Hope in the United States. Bibliometric indicators report 65 indexed documents, more than 6,300 citations, and an h-index of 28. These metrics suggest sustained scholarly engagement and measurable visibility within the scientific community, particularly in immunotherapy-related disciplines.[1]

Research Contributions

Research contributions attributed to Mohamed Husseiny Elsayed include studies exploring immune responses, cancer therapeutics, and translational research methodologies. His collaborative publications have supported scientific understanding of treatment optimization and biological mechanisms relevant to disease management. Such work aligns with contemporary priorities in precision medicine and advanced therapeutic development.[4]

Publications

The publication record of Mohamed Husseiny Elsayed includes 65 scholarly documents in immunotherapy and translational oncology, reflecting sustained research productivity, scientific collaboration, and contributions to advancing biomedical knowledge and therapeutic innovation.[4]

Research Impact

Citation activity represents one indicator of scientific influence and knowledge dissemination. With thousands of citations recorded across indexed publications, the researcher demonstrates meaningful engagement from the academic community. The observed citation profile suggests that published findings have contributed to ongoing discussions and developments within biomedical research fields.[3]

Award Suitability

Evaluation for the Innovative Research Award considers originality, scholarly productivity, scientific influence, and relevance to advancing healthcare knowledge. Based on available academic indicators, Mohamed Husseiny Elsayed demonstrates characteristics commonly associated with recognized research excellence. His publication record, citation performance, and institutional affiliation collectively support consideration within competitive academic recognition programs.[2]

Conclusion

The academic profile presented in this article highlights measurable research activity and scholarly engagement within the field of immunotherapy. Bibliometric indicators, institutional affiliation, and documented scientific contributions collectively illustrate an established research trajectory. These characteristics provide a foundation for recognition within academic and professional award frameworks dedicated to scientific innovation.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Mohamed Husseiny Elsayed, Author ID 8580986700. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=8580986700
  2. ORCID. (n.d.). Researcher Profile: Mohamed Husseiny Elsayed.
    https://orcid.org/0000-0002-3470-2858
  3. Cobb, J., Rawson, J., Gonzalez, N., Kandeel, F., & Husseiny, M. I. (n.d.). Oral tolerogenic vaccine combined with gastrin restores immune tolerance and beta-cell function in NOD mice with type 1 diabetes.
    https://pubmed.ncbi.nlm.nih.gov/41635853/
  4. Singer, M., Hamdy, R., Ghonaim, J.H., & Husseiny, M.I. Metabolic Imbalance in Immune Cells in Relation to Metabolic Disorders, Cancer, and Infections.
    https://link.springer.com/chapter/10.1007/978-981-96-1305-2_9

Ranjith Kumavath | Drug Repurposing | Research Excellence Award

Published on by Top Pharmaceutical

Research Excellence Award

Ranjith Kumavath
Affiliation Pondicherry University
Country India
Scopus ID 13907540500
Documents 98
Citations 1927
h-index 25
Subject Area Drug Repurposing
Event International Top Pharmaceutical Awards
ORCID 0000-0002-0751-5491

Ranjith Kumavath – Pondicherry University

Ranjith Kumavath of Pondicherry University is a researcher whose scholarly activities are associated with the field of drug repurposing, an interdisciplinary area that integrates pharmaceutical sciences, molecular biology, computational approaches, and translational medicine. This article presents a structured academic overview prepared in the style of a scholarly reference entry, highlighting research profile indicators, publication activity, research impact metrics, and considerations relevant to recognition through the Research Excellence Award at the International Top Pharmaceutical Awards.[1]

Abstract

This academic profile summarizes the scholarly record of Ranjith Kumavath, emphasizing research productivity, citation performance, and contributions within the domain of drug repurposing. Available bibliometric indicators indicate sustained publication activity and measurable scholarly influence through citations and an established h-index. The profile further examines research relevance, interdisciplinary engagement, and potential alignment with the objectives commonly associated with scientific recognition programs and research excellence awards.[1][2]

Keywords

Drug Repurposing; Pharmaceutical Research; Translational Medicine; Research Impact; Bibliometrics; Scopus; Scientific Publications; Citation Analysis; Academic Recognition; Research Excellence.

Introduction

Drug repurposing has emerged as an important strategy in modern pharmaceutical research due to its potential to identify new therapeutic applications for existing compounds while reducing development timelines and associated costs. Researchers working in this area frequently integrate experimental and computational methodologies to evaluate candidate molecules, biological targets, and disease mechanisms. Within this context, the academic record of Ranjith Kumavath reflects engagement with topics relevant to pharmaceutical innovation and translational research.[3]

Research Profile

According to the reported bibliometric indicators, the researcher has accumulated 98 indexed documents, 1,927 citations, and an h-index of 25. These indicators are commonly used to evaluate scholarly productivity and the influence of published work within academic literature.[1]

Research Contributions

The researcher’s contributions are associated with investigations involving therapeutic discovery, molecular mechanisms of disease, computational screening approaches, and the identification of alternative clinical applications for existing pharmaceutical compounds. Such work contributes to broader scientific efforts aimed at improving therapeutic efficiency and expanding treatment opportunities through evidence-based repurposing strategies.[3][2]

Publications

Publication activity constitutes an important component of academic evaluation. The available metrics indicate a substantial body of indexed scholarly work. Representative literature within the broader field of drug repurposing demonstrates the significance of systematic approaches for identifying therapeutic opportunities and validating candidate compounds through experimental and computational frameworks.[3]

Research Impact

Bibliometric indicators suggest that the researcher’s publications have been cited by subsequent scholarly works, indicating engagement with the scientific community and continued relevance within ongoing research discussions. Citation counts and h-index values are commonly considered alongside qualitative assessments when evaluating academic impact and research influence.[1][2]

Award Suitability

Academic awards commonly consider factors such as publication productivity, citation influence, research originality, interdisciplinary engagement, and contributions to scientific advancement. Based on the reported academic indicators, the profile demonstrates characteristics frequently reviewed during recognition processes. Final determinations regarding awards remain subject to the criteria, peer review procedures, eligibility requirements, and evaluation standards established by the awarding organization.[3]

Conclusion

Ranjith Kumavath’s academic profile reflects a documented record of research activity associated with drug repurposing and related pharmaceutical sciences. The available bibliometric indicators demonstrate established scholarly productivity and measurable citation impact. As a reference-style overview, this article summarizes key aspects of research performance, publication activity, and academic visibility relevant to scientific recognition and professional evaluation.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Ranjith Kumavath, Author ID 13907540500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=13907540500
  2. ORCID. (n.d.). ORCID record for Ranjith Kumavath.
    https://orcid.org/0000-0002-0751-5491
  3. P. V., Thomas, N. M., Ranjith, N. K., Muripiti, V., & Banothu, J. (n.d.). Pyrimidine derivatives as anti-HIV agents: Advances and structure–activity relationship insights.
    https://www.sciencedirect.com/science/article/abs/pii/S002228602601639X

Gabriela Kot | Rheumatology | Young Scientist Award

Published on by Top Pharmaceutical

Young Scientist Award

Gabriela Kot
Affiliation Poznan University of Medical Sciences
Country Poland
Scopus ID 59492769200
Documents 7
Citations 9
h-index 2
Subject Area Rheumatology
Event International Top Pharmaceutical Awards
ORCID 0009-0004-3205-6225

Gabriela Kot – Poznan University of Medical Sciences

Gabriela Kot is a researcher affiliated with Poznan University of Medical Sciences in Poland, with scholarly activity documented across rheumatology, clinical medicine, gastrointestinal research, and related biomedical fields. Her ORCID record identifies seven works and provides evidence of continued engagement with peer-reviewed research. [1] Her publication portfolio includes studies addressing rheumatoid arthritis, monoclonal antibody therapy, thrombotic microangiopathy, digestive-system biology, and clinical outcomes. [2]

Abstract

Gabriela Kot’s documented research activity represents a multidisciplinary biomedical profile with particular relevance to rheumatology and clinical research. Her record includes seven works, while the supplied bibliometric information reports nine citations and an h-index of 2. The publication record includes observational research, therapeutic comparisons, case-based clinical investigation, and studies of disease mechanisms. Her work on rheumatoid arthritis and monoclonal antibodies is especially aligned with pharmaceutical and therapeutic research, providing a relevant basis for consideration within a Young Scientist Award framework. [3]

Keywords

Gabriela Kot; Young Scientist Award; Rheumatology; Rheumatoid Arthritis; Monoclonal Antibodies; Clinical Research; Therapeutics; Thrombotic Microangiopathy; Biomedical Research; Pharmaceutical Research.

Introduction

The research record of Gabriela Kot demonstrates participation in contemporary biomedical investigations spanning rheumatology, clinical medicine, gastroenterology, nephrology, and therapeutic science. The available ORCID information confirms employment at the Poznan University of Medical Sciences and lists seven research works. [1] This breadth indicates an interdisciplinary approach in which clinical observations and disease-focused studies contribute to the broader evidence base.

Research Profile

The supplied profile identifies Rheumatology as the principal subject area and reports seven documents, nine citations, and an h-index of 2. Her publications include research concerning rheumatoid arthritis, particularly antinuclear antibodies and monoclonal antibody treatment, alongside investigations in other clinical domains. The profile therefore reflects developing research experience supported by a varied publication portfolio.[4]

Research Contributions

Among the documented contributions is a cross-sectional observational study examining antinuclear antibodies in rheumatoid arthritis, providing clinical evidence relevant to disease characterization. [4] Another publication compares the efficacy and safety of monoclonal antibodies in rheumatoid arthritis, directly connecting her research activity with therapeutic evaluation. [5] Additional works address rare clinical complications, gastrointestinal biology, surveillance, and quality-of-life outcomes.

Publications

The publication record contains seven works listed in the supplied ORCID document, including journal articles published in 2024, 2025, and 2026. [1] The works include studies in Antibodies, Cancers, Medicina, Biochemical and Biophysical Research Communications, and the American Journal of Case Reports. Several records provide DOI identifiers, enabling direct verification through publisher or DOI services.[4]

Research Impact

The supplied bibliometric profile records nine citations and an h-index of 2, indicating measurable scholarly uptake of the documented publications. [3] The research themes also have practical relevance because they encompass therapeutic safety, disease assessment, clinical surveillance, and patient outcomes. Continued publication in peer-reviewed journals and further development of focused rheumatology research may strengthen the long-term visibility and impact of this emerging research profile.[4]

Award Suitability

Gabriela Kot’s documented publication activity and identified subject area provide a reasonable scholarly basis for consideration for the Young Scientist Award. Her work directly includes rheumatoid arthritis and monoclonal antibody research, subjects relevant to pharmaceutical and therapeutic sciences. [4] The multidisciplinary nature of her other publications further demonstrates engagement with clinically relevant biomedical questions, although award decisions should remain subject to the formal evaluation criteria of the International Top Pharmaceutical Awards. [1]

Conclusion

Gabriela Kot has an emerging research profile centered on rheumatology and supported by publications across several biomedical disciplines. The available record documents seven works, nine citations, and an h-index of 2, together with research addressing rheumatoid arthritis, therapeutic antibodies, clinical complications, and related medical questions.These activities establish a relevant foundation for continued scientific development and consideration within an early-career research recognition framework. [1]

References

  1. Elsevier. (n.d.). Scopus author details: Gabriela Kot, Author ID 59492769200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59492769200
  2. Kot, G., et al. (2026). Diagnostic Challenges in Atypical Hemolytic Uremic Syndrome: A Case of Artificial Mitral Valve Dysfunction as a Possible Trigger for Severe Thrombotic Microangiopathy. American Journal of Case Reports. DOI: 10.12659/AJCR.948516.
    https://doi.org/10.12659/AJCR.948516
  3. Cholerzyńska, H., Kot, G., Świątek, Ł., & Grygiel-Górniak, B. (2026). Beyond the Surface: Antinuclear Antibodies in Rheumatoid Arthritis—Experiences from a Single-Center, Cross-Sectional Observational Study. Antibodies, 15(4), 58. DOI: 10.3390/antib15040058.
    https://doi.org/10.3390/antib15040058
  4. Kot, G., Świątek, Ł., Sikorska, D., & Samborski, W. (2025). Comparative efficacy and safety of monoclonal antibodies in rheumatoid arthritis. Wydawnictwo Akademia Medycyny. DOI: 10.53139/FW.20251806.
    https://doi.org/10.53139/FW.20251806
  5. ORCID. (2026). Gabriela Kot, ORCID record and works. ORCID.
    https://orcid.org/0009-0004-3205-6225